4). Posology Dosage should be tailored according to the individual’s needs and responses and should be reduced in renal impairment. Plasma magnesium concentrations should be measured to determine the rate and duration of infusion and should be monitored throughout therapy.
1 mL <Magnesium sulfate> 50% w/v contains 500 mg magnesium sulfate heptahydrate corresponding to approximately 2 mmol (49 mg = 4 mEq) magnesium ions. 1 mmol Mg2+. For the intravenous route, the 50% w/v solution requires dilution to a concentration of not more than 20%.
For instructions on dilution of <Magnesium sulfate> 50% w/v to a 20% w/v solution see section “Method of administration”.
Posology Treatment of magnesium deficiency in proven hypomagnesaemia Adults:
Intravenous route: intravenous infusion Up to 80 mL Magnesium sulfate 50% w/v solution diluted in an infusion solution should be administered by slow intravenous infusion over a period of up to five days and titrated to clinical need.
The usual regimen is 16 – 24 mL Magnesium sulfate 50% w/v solution diluted in an infusion solution in the first 24 hours followed by 8 – 12 mL Magnesium sulfate 50% w/v solution diluted in an infusion solution per day for 3 or 4 days, administered by intravenous infusion.
Intramuscular route: 2 – 4 mL Magnesium sulfate 50% w/v solution undiluted or diluted (4 – 8 mL of a 25% w/v solution) can be given intramuscularly every 6 hours for 24 hours (a total of 4 doses). 5 mL/kg bw of a 20% w/v solution) every 6 – 12 hours as required, to be given by intravenous injection over at least 10 minutes.
25 mL/kg bw of a 20% w/v solution) every 12 hours as required, to be given by intravenous injection over at least 10 minutes. Adolescent 12 – 17 years 2 mL Magnesium sulfate 50% w/v solution diluted (5 mL of a 20% w/v solution) every 12 hours as required, to be given by intravenous injection over at least 10 minutes.
Prevention of hypomagnesaemia in patients receiving total parenteral nutrition Adults: Intravenous route: intravenous infusion 5 – 10 mL Magnesium sulfate 50% w/v solution daily, diluted in an infusion solution, usual dose 6 mL Magnesium sulfate 50% w/v solution daily, diluted in an infusion solution, to be given by intravenous infusion.
1 mL/kg Magnesium sulfate 50% w/v solution daily, diluted in an infusion solution, to be given by intravenous infusion. 05 mL/kg Magnesium sulfate 50% w/v solution daily, diluted in an infusion solution, to be given by intravenous infusion.
Control and prevention of recurrent seizures in severe pre-eclampsia and eclampsia Adult women: Loading dose given by intravenous injection: An initial IV loading dose of approximately 8 – 10 mL Magnesium sulfate 50% w/v solution diluted (20 – 25 mL of a 20% w/v solution) is administered over 5 – 15 minutes, followed either by maintenance intravenous infusion or regular IM injections for 24 hours, as follows: IV Maintenance Regimen The IV loading dose (above) is followed by an infusion of approximately 2 mL Magnesium sulfate 50% w/v solution per hour, diluted in an infusion solution, for at least 24 hours after the last fit.
IM Maintenance Regimen The IV loading dose (above) is immediately followed by deep IM injection of 10 mL Magnesium sulfate 50% w/v solution undiluted. Maintenance therapy is a further 10 mL Magnesium sulfate 50% w/v solution undiluted IM every four hours, continued for 24 hours after the last fit (provided respiratory rate is > 16/min, urine output > 25mL/min and knee jerks are present).
Recurrent convulsions:
In both IV and IM regimens, a further 4 – 8 mL Magnesium sulfate 50% w/v solution diluted (10 – 20 mL of a 20% w/v solution) depending on body weight are given as intravenous injection over a period of 5 minutes. If the body weight is less than 70 kg, 4 mL Magnesium sulfate 50% w/v solution diluted (10 mL of a 20% w/v solution) are given as intravenous injection over a period of 5 minutes.
3) Patients with mild to moderate renal impairment should receive 50% of the dosage recommended for patients with normal kidney function. Patients with impaired liver function There are no recommended special dosage instructions for patients with impaired liver function because of insufficient data.
Elderly:
There are no specific recommendations for dosage in elderly adults. Magnesium sulfate 50% w/v solution should be used with caution in elderly because of often renal impairment in this age group. Method of administration Intravenous use Concentrations of no higher than 20% w/v should be given intravenously.
9%. , dilute a 10 mL ampoule Magnesium sulfate 50% w/v solution with 15 mL diluent to get 25 mL of a 20% w/v solution).
Intravenous use in adults and adolescents:
For intravenous infusion, administer via a volumetric infusion device at a rate appropriate to the indication (see posology above). For intravenous injection, give by slow IV injection at a rate […]